Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pluristyx Launches PluriFreeze Cryopreservation Media | Contract Pharma

What are you searching for?

Sign in
Breaking News

Pluristyx Launches PluriFreeze Cryopreservation Media

Designed to support cell metabolism and ease pluripotent stem and other energetically active cells to and from the frozen state.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Pluristyx, a provider of tools, technologies, and services for cell therapies, has released its cryopreservation medium solution, PluriFreeze. Currently available in a Research Use Only (RUO) formulation, with a Good Manufacturing Practice (GMP) version to be released in future, PluriFreeze adds to the company’s Pluristyx’s panCELLa Platform for iPSC therapeutic development, with broad applicability for other sensitive cell types.
 
PluriFreeze is designed to support cell metabolism and ease pluripotent stem and other energetically active cells to and from the frozen state to enhance post-thaw viability and function. PluriFreeze offers benefits for cell therapy development that include an entirely synthetic and Animal-Origin Free (AOF) composition, low viscosity for automation and large-scale cell production, and a companion DMSO-free PluriPrep wash solution to enable extended processing times. Additionally, PluriFreeze is formulated with components Generally Recognized As Safe (GRAS) by the U.S. Federal Food, Drug, and Cosmetic Act.   
 
Ben Fryer, CEO of Pluristyx, said, “Our goal as an organization is to be a problem-solving partner for our customers, and one of the long-standing challenges for cell therapy developers has been the availability of high-performing, scalable, and cost-effective cryopreservation formulations. The launch of PluriFreeze represents a significant step forward in our commitment to providing comprehensive solutions for iPSCs with an entirely synthetic and AOF workflow. The strong compatibility of PluriFreze with our PluriBank, clinical-grade, pre-edited iPSCs, allows us to offer an integrated approach to our customers.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics